FitManitoba
FILE PHOTO: A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls
(Reuters) – GlaxoSmithKline’s HIV treatments division said on Friday that Canada’s healthcare regulator has approved its long-acting HIV injection, in a major win for the British drugmaker after a U.S. rejection late last year.
GSK’s ViiV Healthcare said that Health Canada had given the green light to Cabenuva, a monthly injection to suppress the virus that causes AIDS and is aimed as an alternative to daily pills. (bit.ly/3aatmo8)
Reporting by Pushkala Aripaka in Bengaluru; Editing by Vinay Dwivedi
Our Standards:The Thomson Reuters Trust Principles.
View original article here Source
